Recent developments in antimalarial drug discovery

[Display omitted] Although malaria remains a big burden to many countries that it threatens their socio-economic stability, particularly in the countries where malaria is endemic, there have been great efforts to eradicate this disease with both successes and failures. For example, there has been a...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2023-06, Vol.88-89, p.117339-117339, Article 117339
Main Authors: Umumararungu, Théoneste, Nkuranga, Jean Bosco, Habarurema, Gratien, Nyandwi, Jean Baptiste, Mukazayire, Marie Jeanne, Mukiza, Janvier, Muganga, Raymond, Hahirwa, Innocent, Mpenda, Matabishi, Katembezi, Alain Nyirimigabo, Olawode, Emmanuel Oladayo, Kayitare, Egide, Kayumba, Pierre Claver
Format: Article
Language:English
Subjects:
Antimalarials - pharmacology
Antimalarials - therapeutic use
Chloroquine - pharmacology
Clinical trial
Drug development
Drug Resistance
Folic Acid Antagonists - pharmacology
Humans
Malaria
Malaria - drug therapy
Malaria, Falciparum - drug therapy
Mechanism of action
Plasmodium
Plasmodium falciparum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Although malaria remains a big burden to many countries that it threatens their socio-economic stability, particularly in the countries where malaria is endemic, there have been great efforts to eradicate this disease with both successes and failures. For example, there has been a great improvement in malaria prevention and treatment methods with a net reduction in infection and mortality rates. However, the disease remains a global threat in terms of the number of people affected because it is one of the infectious diseases that has the highest prevalence rate, especially in Africa where the deadly Plasmodium falciparum is still widely spread. Methods to fight malaria are being diversified, including the use of mosquito nets, the target candidate profiles (TCPs) and target product profiles (TPPs) of medicine for malarial venture (MMV) strategy, the search for newer and potent drugs that could reverse chloroquine resistance, and the use of adjuvants such as rosiglitazone and sevuparin. Although these adjuvants have no antiplasmodial activity, they can help to alleviate the effects which result from plasmodium invasion such as cytoadherence. The list of new antimalarial drugs under development is long, including the out of ordinary new drugs MMV048, CDRI-97/78 and INE963 from South Africa, India and Novartis, respectively.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2023.117339